Manufacturing

Through a collaboration, Avantor and Cytovance Biologics will accelerate plasmid optimization and sourcing services for viral vectors and mRNA-based vaccines and therapeutics.

PCI Pharma Services is investing $100 million in manufacturing capabilities and capacity expansion to its Bedford, NH facility.

Further development of nucleic acid-based therapeutics has been accelerated by the recent success of mRNA vaccines.

Outsourcing partners are ready to fill the market need for greater cell therapies capacities.

MilliporeSigma’s ZooMAb antibodies have been recognized for their low environmental impact by My Green Lab.

The new company has been appointed as a channel partner for Ireland by TSI Inc., a particle counter manufacturer.

An increasingly complex development pipeline and industry considerations, such as sustainability, are leading to a greater need for more efficient separation and purification in downstream processing.

Complex hurdles complicate the development of emerging therapies.

Plant-based manufacturing technology gains mainstream edge in biopharmaceutical production.

Workforce training is crucial for biopharmaceutical manufacturing.

Understanding both the challenges and solutions of aseptic manufacturing.

This article summarizes industry views on PAT in bioprocess-related applications and presents a vision for the biopharmaceutical industry to achieve Industry 4.0.

Applying modeling methods in preclinical studies can be a powerful tool for generating data and shortening development timelines.

The SamuxMP enables routine quantification of empty/full AAV capsid ratios

Societal CDMO has been awarded a new manufacturing and packaging task order agreement by National Cancer Institute.

FDA has approved commercial production at Kite’s new CAR T-cell therapy manufacturing facility in Frederick, Maryland.

Catalent will invest $350 million into integrated biologics drug substance and drug product manufacturing at Bloomington, Indiana facility.

The European Investment Bank has provided €15 million to fund coronavirus research at IRBM.

Otsuka Pharmaceutical and Osaka University have entered an exclusive license agreement on a new anti-tumor antibody.

High Purity New England has launched its third facility, focused on single-use assemblies.

ReiThera and Exothera are collaborating to develop a large-scale, low-cost-per-dose manufacturing process to deliver novel vaccines to low and middle-income countries.

Achilles Therapeutics has announced that it will expand its clinical manufacturing capabilities in the UK and enter a partnership agreement for expansion in the US.

Tjoapack has doubled its packaging capacity with the completion of its Netherlands facility expansion.

VectorBuilder will expand with the construction of new $500 million Gene Delivery Research and Manufacturing Campus in Guangzhou, China.

Opus enters a strategic collaboration with Resilience for AAV-based gene therapy development and manufacturing for inherited retinal diseases.